Search Results - "Hölscher, Christian"

Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models by Hölscher, Christian

“…Type 2 diabetes is a risk factor for several chronic neurodegenerative disorders such as Alzheimer's or Parkinson's disease. The link appears to be insulin…”
Get full text

Brain insulin resistance: role in neurodegenerative disease and potential for targeting by Hölscher, Christian

“…: This review evaluates the novel strategy of treating Alzheimer's and Parkinson's disease (AD and PD) withdrugs that initially have been developed to treat…”
Get more information

Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders by Hölscher, Christian

“…Type 2 diabetes mellitus and the associated desensitisation of insulin signalling has been identified as a risk factor for progressive neurodegenerative…”
Get full text

Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making? by Hölscher, Christian

“…Parkinson's disease (PD) is a complex syndrome for which there is no disease-modifying treatment on the market. However, a group of drugs from the…”
Get full text

Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer's Disease by Hölscher, Christian

“…Type 2 diabetes is a risk factor for developing Alzheimer's disease (AD). The underlying mechanism that links up the two conditions seems to be the…”
Get full text

The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review by Reich, Niklas, Hölscher, Christian

“…Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's disease (AD and PD) and that includes the highly controversial…”
Get full text

Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases by Hölscher, Christian

“…The incretin hormone glucagon-like peptide 1 (GLP-1) has many effects in the body. It is best known for the ‘incretin effect’, facilitating insulin release…”
Get full text

GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models by Zhang, Zhen Qiang, Hölscher, Christian

“…•GIP is a hormone and a growth factor that plays key roles in the brain.•Protease-resistant GIP analogues show neuroprotective effects in animal…”
Get full text

Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases by Hölscher, Christian

“…Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are peptide hormones and growth factors. A major pathological feature of…”
Get full text

Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection by Holscher, Christian

“…The current understanding of neurodegenerative processes in sporadic diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) or multiple sclerosis…”
Get full text

Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer’s and Parkinson’s disease by Reich, Niklas, Hölscher, Christian

“…•CCK promotes hippocampal glutamate release and spatial learning, but blocks consolidation.•CCK-2 receptor activation terminates mesolimbic reward…”
Get full text

Beyond appetite: Acylated ghrelin as a learning, memory and fear behavior-modulating hormone by Reich, Niklas, Hölscher, Christian

“…Although often referred to as a hunger hormone, recent evidence highlights a neuroprotective function of acylated ghrelin (AG) and a substantial role in the…”
Get full text

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis by Hunter, Kerry, Hölscher, Christian

“…Type 2 diabetes is a risk factor for Alzheimer's disease (AD), most likely linked to an impairment of insulin signalling in the brain. Therefore, drugs that…”
Get full text

Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease by Reich, Niklas, Hölscher, Christian

“…Much thought has been given to the impact of Amyloid Beta, Tau and Alpha-Synuclein in the development of Alzheimer's disease (AD) and Parkinson's disease (PD),…”
Get full text

A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model by Shi, Lijuan, Zhang, Zhihua, Li, Lin, Hölscher, Christian

“…•Novel dual GLP-1/GIP receptor agonists are superior to single GLP-1 agonists.•In the icv. STZ model of neurodegeneration, a novel dual agonist was highly…”
Get full text

Therapeutic Potential of Baicalein in Alzheimer’s Disease and Parkinson’s Disease by Li, Yanwei, Zhao, Jinying, Hölscher, Christian

“…Alzheimer’s disease and Parkinson’s disease are the two most common, progressive central neurodegenerative diseases affecting the population over the age of…”
Get full text

Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases by Hölscher, Christian

“…Recently, it has been shown that in patients with AD (Alzheimer's disease) and, to some degree, in patients with PD (Parkinson's disease) insulin signalling is…”
Get more information

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease by McClean, Paula L, Parthsarathy, Vadivel, Faivre, Emilie, Hölscher, Christian

“…Type 2 diabetes is a risk factor for Alzheimer's disease, most likely linked to an impairment of insulin signaling in the brain. The incretin hormone…”
Get full text

The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease by Hölscher, Christian

“…Abstract The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide (GIP) have been developed to treat type 2 diabetes and…”
Get full text

Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease by Tai, Jingjing, Liu, Weizhen, Li, Yanwei, Li, Lin, Hölscher, Christian

“…•A novel triple GLP-1/GIP/glucagon receptor agonist has been developed.•The drug improves memory formation in a mouse model of Alzheimer’s disease.•Amyloid…”
Get full text